Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug (AED) that is approved for the treatment of focal-onset seizures as monotherapy or adjunctive therapy [1,2]. The efficacy and safety/tolerability of ESL as adjunctive therapy for focal-onset seizures in adults have been established in a series of randomised, double-blind, placebo-controlled, Phase III trials [3–6] and long-term extension studies [7–9]. The efficacy and safety/tolerability of ESL in the monotherapy setting have been established in a randomised, double-blind, active-controlled, Phase III trial, conducted in patients with newly diagnosed focal epilepsy [10], and in two randomised, Phase III, withdrawal to monotherapy trials, conducted in patients with uncontrolled focal epilepsy [11,12].
DIC